txt 20151120 hdrsgml 20151120 20151120165705 accession number 000110465915080476 conformed submission type da public document count filed date 20151120 date change 20151120 subject company company data company conformed name depomed inc central index key 0001005201 standard industrial classification pharmaceutical preparation 2834 irs number 943229046 state incorporation fiscal year end 1231 filing value form type da sec act 1934 act sec file number 00553683 film number 151247249 business address street 7999 gateway blvd street suite 300 city newark state zip 94560 business phone 5107448000 mail address street 7999 gateway blvd street suite 300 city newark state zip 94560 filed by company data company conformed name depomed inc central index key 0001005201 standard industrial classification pharmaceutical preparation 2834 irs number 943229046 state incorporation fiscal year end 1231 filing value form type da business address street 7999 gateway blvd street suite 300 city newark state zip 94560 business phone 5107448000 mail address street 7999 gateway blvd street suite 300 city newark state zip 94560 da ascdahtm da security exchange commission washington dc 20549 schedule da rule d solicitationrecommendation statement section d security exchange act 1934 amendment no depomed inc name subject company depomed inc name person filing statement common stock par value title class security 249908104 cusip number class security james schoeneck president chief executive officer 7999 gateway boulevard suite 300 newark california 94560 510 7448000 name address telephone number person authorized receive notice communication behalf person filing statement copy to ryan murr esq eduardo gallardo esq james moloney esq gibson dunn crutcher llp 555 mission street suite 3000 san francisco california 941050921 david kirkland esq john martin esq brian lee esq baker botts llp 1001 page mill road building one suite 200 palo alto california 943041007 check box filing relates solely preliminary communication made commencement tender offer amendment no schedule d amends supplement solicitationrecommendation statement schedule d a amended time time schedule d originally filed depomed inc california corporation depomed company security exchange commission the sec september 14 2015 last amended amendment no filed sec november 2015 except specifically noted herein information set forth schedule d remains unchanged capitalized term used defined amendment no meaning ascribed schedule d item exhibit item hereby amended supplemented adding following exhibit a message employee depomed inc dated november 2015 incorporated reference depomed incs schedule a filed november 2015 a excerpt depomed incs 2015 earnings call incorporated reference depomed incs schedule a filed november 10 2015 a corporate presentation dated november 2015 incorporated reference depomed incs schedule a filed november 18 2015 a press release issued depomed inc november 19 2015 respect withdrawal horizon pharma plcs offer acquire depomed inc filed herewith signature due inquiry best knowledge belief certify information set forth schedule d true complete correct depomed inc by s matthew gosling name matthew gosling title senior vice president general counsel dated november 20 2015 exa aexdahtm exa exhibit a press release depomed comment horizon withdrawal offer acquire company withdrawal follows court ruling enjoining horizons exchange offer proxy solicitation newark calif nov 19 2015 prnewswire depomed inc nasdaq depo depomed company today issued following statement regarding horizon pharma plcs nasdaq hznp horizon decision withdraw acquisition proposal withdrawal follows ruling today santa clara county superior court enjoining horizon pharmas exchange offer proxy solicitation based horizons misuse depomeds confidential information depomeds board management team committed enhancing longterm value look forward continuing execute strategy delivering significant sustainable return shareholder example nucynta franchise is view transformational value driver depomed significantly increase depomeds ebitda cash flow 2015 beyond ultimately strongly believe successfully executed acquisition commercialization strategy depomed bright future independent company thank shareholder input support throughout process importantly want thank employee relentless focus dedication patient family physician provider payer serve morgan stanley co llc leerink partner llc serving financial advisor depomed gibson dunn crutcher llp baker botts llp serving legal counsel depomed depomed specialty pharmaceutical company commercializes product pain neurology related disorder nucynta franchise includes nucynta tapentadol extended release tablet indicated management pain including neuropathic pain associated diabetic peripheral neuropathy dpn severe enough require daily aroundtheclock longterm opioid treatment nucynta tapentadol immediate release version tapentadol management moderate severe acute pain adult gralise gabapentin oncedaily treatment approved management postherpetic neuralgia cambia diclofenac potassium oral solution nonsteroidal antiinflammatory drug indicated acute treatment migraine attack without aura adult 18 year age older zipsor diclofenac potassium liquid filled capsule nonsteroidal antiinflammatory drug indicated relief mild moderate acute pain adult lazanda fentanyl nasal spray intranasal fentanyl drug used manage breakthrough pain adult 18 year age older already routinely taking opioid pain medicine aroundtheclock cancer pain gralise nucynta various partner product candidate formulated depomeds proven proprietary acuform drug delivery technology additional information depomed may found wwwdepomedcom forwardlooking statement statement historical fact contained release forwardlooking statement involve risk uncertainty including limited to related depomeds prospect standalone business depomeds business strategy expectation regarding depomeds future financial result ability create shareholder value expectation regarding anticipated growth future contribution potential nucynta risk detailed companys security exchange commission sec filing including companys annual report form k year ended december 31 2014 recent quarterly report form q inclusion forwardlooking statement regarded representation companys plan objective expectation achieved cautioned place undue reliance forwardlooking statement speak date hereof company undertakes obligation publicly release result revision forwardlooking statement may made reflect event circumstance date hereof reflect occurrence unanticipated event investor contact depomed inc august moretti chief financial officer 5107448000 amorettidepomedcom christopher keenan vp investor relation corporate communication 5107448000 ckeenandepomedcom innisfree ma incorporated larry miller jonathan salzberger scott winter 2127505833 medium contact joele frank wilkinson brimmer katcher eric brielmann 4158693950 andy brimmer averell withers adam pollack 2123554449 graphic gmmijpg graphic begin 644 gmmijpg mcx d vp hpdh dphqdpx mqxq frhdphvrcdrcl ctcdw mvp lpqttittttttttt mtttttttwp l a q mp 04 0 ph p p 0 auarqdtqpt dvrd mahebjaaxbbieeybfjcifizbijksmvmbynlq mqcrmuucvnbxeynhzkqotwgz p p 0 0 ph m 0 w qqaabhhso gadehf mricvsydeueicfvaigtwezh mabfdieffhjdigjfjlktmwnfzplqrgtm muvgxndygzgjotwgzh pvbbba muufi e ghktwskyixwsbo qjoxkzxel maqrujoxsrlvchwcxz mwafhlbzxsap yitnztunqbnpzlnuanp myelifckazuq vogauuaxpzicjrdjguagtgpsxbe l mzpzfhxyueclngvpbbzjjrcylzdzt mvmyqwvjcmmbdqkciheakhu mfxfuucsba kuqpvmxiu rhqnueagkzgkitozate mpqvrqagmlkks zqphiwuvciaa mjvbltmxlwtloujnbwencrlvthyisgub mopmfltaboknvemivymnkhrpebxu mwbmbnyyobgvbkvgomxxjirnt mgmtbwkronlgoocfvnlowhi mohqmveymtfbmkfxndnvamotu ovvxgxz lfevfbn mamtudugrmzfommmqyjduqtirm mmfnnhezlqk nfckmrxqvsitwwmuljutfk mqiiusqkeykzmdfnpkeakmtjxe mxphzuozkvjuiixclhtsoscvqg kgapuogezb mkmhpdwkvszitxjrzmhuvdaroogmkf mdpwoithbx pykbvthhcujnw momtkah r ktjyfknayunsxzxekek mrcaduzuuigyglytezsqaexnmv mmlpljyfdhukw qaegmcvfc agrwz md zxszjqnjmqxmauqdtw mdenbxqfammezfayvkaakzzz rvbzsay mugcbndbgjabhhrfzoovaaczh mwover bwfjnucjzzxfcajqxmlwp mukrfxgxcxbjnieonwp msjsxtzwno dqmxqjluchwabnbbefgg mjylxnmuq bvshgvrcrcviflphmjdb mrn yutg ukskgpxnjwpfyjwhhuhb mo xbwdqsbwphumtqkumogrsduf mkdcgrgtkkhvaszr aiytufe myzgnudeojmrwagp mpmwjgrcrggbiqmiepkddtoofzoxjmm mtbwt deiqdgeisehceelkrykp mniluzwnxcnarmaoan oqozclp mzihqpxmw chrmcttuzhjixdti mja mviytcdhsaoxymla mdlxqqcekvkzaleckjjpxdi mjehkeweyxgidqbjdirhizqrkzh mtmamwovmhvabz ka ddqhwtxz mmkrygjjmjtunckslywgzltfvwnxtzsn mgwkwjz fihhhxpdbhjc hhnldcbcshkgrjze muj ibcrrqjhr mvz wec zgjraejpmlvabv mfkvdbthqzphhhh ivnfvmwbczenyrtsphhhjndscvqoqalcnvc mnqppbbdiemhdplhqjdjsfkuqi m 1110 4444 1110 4444 1110 4444 v end